234 related articles for article (PubMed ID: 35483033)
1. Adjuvant therapy for patients with renal cell carcinoma following surgery: a focus on pembrolizumab.
Serzan M; Atkins MB
Expert Rev Anticancer Ther; 2022 Jun; 22(6):565-574. PubMed ID: 35483033
[TBL] [Abstract][Full Text] [Related]
2. Pembrolizumab outperforms tyrosine kinase inhibitors as adjuvant treatment in patients with high-risk renal cell carcinoma after nephrectomy.
Laukhtina E; Quhal F; Mori K; Sari Motlagh R; Rajwa P; Yanagisawa T; Mostafaei H; König F; Aydh A; Pradere B; Enikeev D; Karakiewicz PI; Schmidinger M; Shariat SF
Eur Urol Oncol; 2022 Feb; 5(1):120-124. PubMed ID: 34992006
[TBL] [Abstract][Full Text] [Related]
3. Post nephrectomy management of localized renal cell carcinoma. From risk stratification to therapeutic evidence in an evolving clinical scenario.
Ciccarese C; Strusi A; Arduini D; Russo P; Palermo G; Foschi N; Racioppi M; Tortora G; Iacovelli R
Cancer Treat Rev; 2023 Apr; 115():102528. PubMed ID: 36905896
[TBL] [Abstract][Full Text] [Related]
4. Adjuvant Pembrolizumab after Nephrectomy in Renal-Cell Carcinoma.
Choueiri TK; Tomczak P; Park SH; Venugopal B; Ferguson T; Chang YH; Hajek J; Symeonides SN; Lee JL; Sarwar N; Thiery-Vuillemin A; Gross-Goupil M; Mahave M; Haas NB; Sawrycki P; Gurney H; Chevreau C; Melichar B; Kopyltsov E; Alva A; Burke JM; Doshi G; Topart D; Oudard S; Hammers H; Kitamura H; Bedke J; Perini RF; Zhang P; Imai K; Willemann-Rogerio J; Quinn DI; Powles T;
N Engl J Med; 2021 Aug; 385(8):683-694. PubMed ID: 34407342
[TBL] [Abstract][Full Text] [Related]
5. Cancer-specific mortality in patients with non-metastatic renal cell carcinoma who have undergone a nephrectomy and are eligible for adjuvant pembrolizumab.
Flammia RS; Hoeh B; Hohenhorst L; Sorce G; Chierigo F; Panunzio A; Tian Z; Saad F; Leonardo C; Briganti A; Antonelli A; Terrone C; Shariat SF; Graefen M; Chun FKH; Montorsi F; Gallucci M; Karakiewicz PI
Semin Oncol; 2022 Apr; 49(2):136-140. PubMed ID: 35610060
[TBL] [Abstract][Full Text] [Related]
6. Perioperative systemic therapy in renal cell carcinoma.
MacPhail C; Wood LA; Thana M
Curr Opin Support Palliat Care; 2023 Dec; 17(4):301-307. PubMed ID: 37800628
[TBL] [Abstract][Full Text] [Related]
7. Adjuvant therapy options in renal cell carcinoma - targeting the metastatic cascade.
Fitzgerald KN; Motzer RJ; Lee CH
Nat Rev Urol; 2023 Mar; 20(3):179-193. PubMed ID: 36369389
[TBL] [Abstract][Full Text] [Related]
8. 2021 Updated European Association of Urology Guidelines on the Use of Adjuvant Pembrolizumab for Renal Cell Carcinoma.
Bedke J; Albiges L; Capitanio U; Giles RH; Hora M; Lam TB; Ljungberg B; Marconi L; Klatte T; Volpe A; Abu-Ghanem Y; Dabestani S; Fernández-Pello S; Hofmann F; Kuusk T; Tahbaz R; Powles T; Bex A
Eur Urol; 2022 Feb; 81(2):134-137. PubMed ID: 34920897
[TBL] [Abstract][Full Text] [Related]
9. Adjuvant immunotherapy for locally advanced renal cell carcinoma.
Alevizakos M; McDermott D
Expert Opin Biol Ther; 2023; 23(12):1265-1275. PubMed ID: 38069655
[TBL] [Abstract][Full Text] [Related]
10. Lenvatinib plus pembrolizumab in patients with either treatment-naive or previously treated metastatic renal cell carcinoma (Study 111/KEYNOTE-146): a phase 1b/2 study.
Lee CH; Shah AY; Rasco D; Rao A; Taylor MH; Di Simone C; Hsieh JJ; Pinto A; Shaffer DR; Girones Sarrio R; Cohn AL; Vogelzang NJ; Bilen MA; Gunnestad Ribe S; Goksel M; Tennøe ØK; Richards D; Sweis RF; Courtright J; Heinrich D; Jain S; Wu J; Schmidt EV; Perini RF; Kubiak P; Okpara CE; Smith AD; Motzer RJ
Lancet Oncol; 2021 Jul; 22(7):946-958. PubMed ID: 34143969
[TBL] [Abstract][Full Text] [Related]
11. Lenvatinib plus pembrolizumab combination therapy for adult patients with advanced renal cell carcinoma.
Ged Y; Lee CH
Expert Rev Anticancer Ther; 2022 Oct; 22(10):1049-1059. PubMed ID: 36154355
[TBL] [Abstract][Full Text] [Related]
12. Pembrolizumab for the treatment of renal cell carcinoma.
Di Bona C; Stühler V; Rausch S; Stenzl A; Bedke J
Expert Opin Biol Ther; 2021 Sep; 21(9):1157-1164. PubMed ID: 34042015
[TBL] [Abstract][Full Text] [Related]
13. Patient-Reported Outcomes in KEYNOTE-564: Adjuvant Pembrolizumab Versus Placebo for Renal Cell Carcinoma.
Choueiri TK; Tomczak P; Park SH; Venugopal B; Symeonides S; Hajek J; Ferguson T; Chang YH; Lee JL; Haas N; Sawrycki P; Sarwar N; Gross-Goupil M; Thiery-Vuillemin A; Mahave M; Kimura G; Perini RF; Saretsky TL; Bhattacharya R; Xu L; Powles T
Oncologist; 2024 Feb; 29(2):142-150. PubMed ID: 37589219
[TBL] [Abstract][Full Text] [Related]
14. [New drug approval: Adjuvant Pembrolizumab in clear-cell renal-cell carcinoma at high risk for recurrence after nephrectomy].
Brunet M; Malouf GG
Bull Cancer; 2022 Sep; 109(9):875-876. PubMed ID: 35778302
[No Abstract] [Full Text] [Related]
15. Adjuvant therapy in renal cell carcinoma in the immunotherapy era: where do we stand?
Zouein J; Naim N; Kourie HR
Immunotherapy; 2023 Feb; 15(2):93-100. PubMed ID: 36601860
[TBL] [Abstract][Full Text] [Related]
16. Adjuvant therapy for renal cell carcinoma in 2023: hopes and disappointments.
Tsimafeyeu I; Basin MF; Bratslavsky G
World J Urol; 2023 Jul; 41(7):1855-1859. PubMed ID: 37310435
[TBL] [Abstract][Full Text] [Related]
17. How to optimize the use of adjuvant pembrolizumab in renal cell carcinoma: which patients benefit the most?
Fallara G; Larcher A; Rosiello G; Raggi D; Marandino L; Martini A; Basile G; Colandrea G; Cignoli D; Belladelli F; Re C; Musso G; Cei F; Bertini R; Briganti A; Salonia A; Montorsi F; Necchi A; Capitanio U
World J Urol; 2022 Nov; 40(11):2667-2673. PubMed ID: 36125505
[TBL] [Abstract][Full Text] [Related]
18. A Plea for Optimizing Selection in Current Adjuvant Immunotherapy Trials for High-risk Nonmetastatic Renal Cell Carcinoma According to Expected Cancer-specific Mortality.
Palumbo C; Mazzone E; Mistretta FA; Knipper S; Perrotte P; Shariat SF; Saad F; Kapoor A; Lattouf JB; Simeone C; Briganti A; Antonelli A; Karakiewicz PI
Clin Genitourin Cancer; 2020 Aug; 18(4):314-321.e1. PubMed ID: 32482565
[TBL] [Abstract][Full Text] [Related]
19. The 2022 Updated European Association of Urology Guidelines on the Use of Adjuvant Immune Checkpoint Inhibitor Therapy for Renal Cell Carcinoma.
Bedke J; Albiges L; Capitanio U; Giles RH; Hora M; Ljungberg B; Marconi L; Klatte T; Volpe A; Abu-Ghanem Y; Dabestani S; Fernández-Pello S; Hofmann F; Kuusk T; Tahbaz R; Powles T; Bex A
Eur Urol; 2023 Jan; 83(1):10-14. PubMed ID: 36511268
[TBL] [Abstract][Full Text] [Related]
20. Adjuvant Vascular Endothelial Growth Factor-targeted Therapy in Renal Cell Carcinoma: A Systematic Review and Pooled Analysis.
Sun M; Marconi L; Eisen T; Escudier B; Giles RH; Haas NB; Harshman LC; Quinn DI; Larkin J; Pal SK; Powles T; Ryan CW; Sternberg CN; Uzzo R; Choueiri TK; Bex A
Eur Urol; 2018 Nov; 74(5):611-620. PubMed ID: 29784193
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
